SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin shines as its arm receives USFDA approval for generic Avapro Tablets

17 Oct 2012 Evaluate

Lupin is currently trading at Rs. 562.90, up by 9.35 points or 1.32% from its previous closing of Rs. 555.55 on the BSE.

The scrip opened at Rs. 557.00 and has touched a high and low of Rs. 564.80 and Rs. 556.65 respectively. So far 1, 90,430 shares were traded on the counter.

The BSE stock of face value Rs. 2 has touched a 52 week high of Rs. 631.95 on 10-Sep-2012 and a 52 week low of Rs. 408.20 on 14-Dec-2011.

The promoters holding in the company stood at 46.89% while Institutions and Non-Institutions held 43.37% and 9.75% respectively.

Lupin’s subsidiary - Lupin Pharmaceuticals Inc. has received final approval for its Irbesartan Tablets 75mg, 150mg and 300mg from the United States Food and Drugs Administration (USFDA) to market a generic version of Sanofi Aventis US, LLC’s (Sanofi Aventis) Avapro Tablets, 75mg, 150mg and 300mg strengths.

Lupin’s Irbesartan Tablets 75mg, 150mg and 300mg are the AB-rated generic equivalent of Sanofi Aventis’s Avapro Tablets. Irbesartan is an angiotensin II receptor antagonist and is indicated for the treatment of Hypertension and Nephropathy in Type 2 Diabetic patients. Avapro Tablets had annual US sales of approximately $400.7 million (IMS MAT June 2012 sales).

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2356.55 17.10 (0.73%)
23-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1867.80
Dr. Reddys Labs. 1301.30
Cipla 1433.10
Zydus Lifesciences 1112.10
Lupin 2356.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: